FDA accepts for filing Cladribine Tablets NDA for MS
FDA accepts for filing Cladribine Tablets NDA for MS
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS).
Read more on News-Medical-Net
